Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Ottawa

$17,500.00

Characterization of novel viral sensitizers that enhance oncolytic herpes simplex-1 virus (HSV1) and vesicular stomatitis virus (VSV) infection in cancer cells through polo-like kinase-1(PLK1) inhibition

EF 2019-20

Résumé
"The oncolytic herpes simplex virus 1 (oHSV1) is FDA-approved for the treatment of advanced melanoma, while rhabdoviruses (e.g. Vesicular Stomatitis Virus (oVSV)) are undergoing clinical investigation. OVs are genetically engineered to enhance tumour tropism and reduce virulence within healthy tissue by attenuating their capacity for innate immune evasion. While this maximize clinical safety, as a result replication within tumour tissue is also reduced. Since productive replication is critical for therapeutic efficacy of these viral agents, this represents a significant barrier to the clinical translation of standalone virotherapy. The identification of pharmacological compounds capable of improving viral replication in tumours is therefore perceived to be of great clinical value. I have discovered that the targeted anticancer drugs, BI2536 and BI6727, both specific polo-like kinase-1 (PLK1) inhibitors, dose dependently potentiate productive viral infection to unforeseen levels in glioblastoma cell lines. I hypothesize that pharmacoviral combination of BI6727 and BI2536 with oHSV1 and oVSV will strongly augment oncolysis and anti-tumour immune responses. The primary objectives of my project are: (1) To characterize oncolysis from this pharmacoviral approach by examining viral spread, viral protein expression, cell viability, and production of viral progeny in both normal and cancer cells. (2) To elucidate the mechanistic target(s) by which BI2536 and BI6727 synergize with oHSV1 and oVSV infection in cancer cells by performing kinase specific knockdown and signaling pathway analysis. My studies have the potential to uncover a novel mechanistic target that could greatly improve the therapeutic efficacy of novel and promising viral immunotherapeutics."
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
428819
Name
Gilchrist Victoria
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterization of novel viral sensitizers that enhance oncolytic herpes simplex-1 virus (HSV1) and vesicular stomatitis virus (VSV) infection in cancer cells through polo-like kinase-1(PLK1) inhibition
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Glioblastoma; Herpes Simplex Virus 1 (Hsv1); Kinase Inhibitors; Oncolytic Virus; Polo-Like Kinase 1 (Plk1); Vesicular Stomatitis Virus (Vsv); Viral Sensitizer
Abstract
"The oncolytic herpes simplex virus 1 (oHSV1) is FDA-approved for the treatment of advanced melanoma, while rhabdoviruses (e.g. Vesicular Stomatitis Virus (oVSV)) are undergoing clinical investigation. OVs are genetically engineered to enhance tumour tropism and reduce virulence within healthy tissue by attenuating their capacity for innate immune evasion. While this maximize clinical safety, as a result replication within tumour tissue is also reduced. Since productive replication is critical for therapeutic efficacy of these viral agents, this represents a significant barrier to the clinical translation of standalone virotherapy. The identification of pharmacological compounds capable of improving viral replication in tumours is therefore perceived to be of great clinical value. I have discovered that the targeted anticancer drugs, BI2536 and BI6727, both specific polo-like kinase-1 (PLK1) inhibitors, dose dependently potentiate productive viral infection to unforeseen levels in glioblastoma cell lines. I hypothesize that pharmacoviral combination of BI6727 and BI2536 with oHSV1 and oVSV will strongly augment oncolysis and anti-tumour immune responses. The primary objectives of my project are: (1) To characterize oncolysis from this pharmacoviral approach by examining viral spread, viral protein expression, cell viability, and production of viral progeny in both normal and cancer cells. (2) To elucidate the mechanistic target(s) by which BI2536 and BI6727 synergize with oHSV1 and oVSV infection in cancer cells by performing kinase specific knockdown and signaling pathway analysis. My studies have the potential to uncover a novel mechanistic target that could greatly improve the therapeutic efficacy of novel and promising viral immunotherapeutics."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Gilchrist, Victoria
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~